Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 14, 2025 09:30 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th International Conference on Malignant Lymphoma

SAN FRANCISCO, May 14, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
April 25, 2025 13:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets

Nurix's lead BTK degrader, bexobrutideg, demonstrates exceptional efficiency, with a single molecule degrading approximately 10,000 copies of BTK per hour BRAF degrader demonstrates broad activity...
March 17, 2025 07:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia

First-in-class BTK degrader, NX-5948, Granted ODD for WM and assigned nonproprietary name “bexobrutideg” in newly named degrader class of drugs
December 19, 2024 07:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom’s Macroglobulinemia

SAN FRANCISCO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...
November 20, 2024 16:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia

The PRIME initiative provides enhanced support to developers of promising medicines to optimize development plans and accelerate evaluation Pivotal trials of NX-5948 are planned to initiate in 2025 ...
November 17, 2024 10:30 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024

SAN FRANCISCO, Nov. 17, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...
November 05, 2024 09:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Announces Presentations at the 66th American Society of Hematology (ASH) Annual Meeting

SAN FRANCISCO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...
October 21, 2024 16:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Announces Presentations at the 7th Annual TPD & Induced Proximity Summit

Presentations will summarize new preclinical data from brain-penetrant, pan-mutant B-Raf degrader program and recent clinical data from NX-5948 BTK degrader program Members of the Nurix management...
October 19, 2024 08:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom’s Macroglobulinemia

NX-5948 demonstrated robust clinical activity with objective responses observed in 7 of 9 (77.8%) evaluable Waldenstrom’s patients in the ongoing Phase 1a/1b clinical trial Responses are durable and...
June 10, 2024 07:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics to Host a Webcast and Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of NX-5948 Being Presented at the European Hematology Association Congress (EHA2024)

SAN FRANCISCO, June 10, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...

Next Page keyboard_arrow_right